EPISODE · Jun 9, 2026 · 16 MIN
Treat-to-Target in Hereditary Angioedema
from All Things Angioedema – Learning about angioedema with Dr. Thomas Buttgereit · host ACARE, the Global Allergy and Asthma Excellence Network for Angioedema
In this episode of All Things Angioedema, Dr. Thomas Buttgereit speaks with Dr. Isabelle Boccon-Gibod from the French ACARE center in Grenoble about the new European expert consensus on applying a treat-to-target (T2T) approach in hereditary angioedema (HAE). The discussion explores how goal-oriented care can improve consistency and patient outcomes in daily clinical practice. They discuss:🔹 What does a treat-to-target approach mean in HAE management? 🔹 How does T2T differ from traditional guideline-based treatment? 🔹 What are the short-term and long-term goals in HAE care? 🔹 Why are patient-reported outcome measures (PROMs) so important? 🔹 What challenges exist when implementing T2T in clinical practice? 🔹 How could this consensus influence future guidelines and research? Dr. Boccon-Gibod explains how structured monitoring, shared decision-making, and clearly defined treatment goals can help move HAE care closer to the ultimate aim of “normalization of life.” The episode highlights the importance of individualized care and practical strategies for improving disease control and quality of life. Key Learnings from the Episode:Treat-to-target introduces a structured, goal-oriented approach to HAE care. The approach combines short-term symptom control with long-term quality-of-life goals. Normalization of life is the ultimate treatment target in HAE. Patient-reported outcome measures are central to monitoring disease control. The AECT is an important tool for assessing HAE control in practice. Shared decision-making plays a key role in treatment planning. Clinical practice and access to therapies still vary across countries. Structured follow-up can improve consistency of care. T2T may influence future HAE guidelines and clinical research. The approach aims to improve long-term outcomes for patients with HAE. Chapters:00:00 Introduction to Angioedema and the Podcast01:04 Understanding the Treat-to-Target Approach02:15 The Role of Patient-Reported Outcome Measures10:19 Challenges in Implementing the T2T Approach12:16 Impact of Consensus on Future Research and GuidelinesDo you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form ATA: https://forms.office.com/e/ZWxx3D4Cmr
What this episode covers
In this episode of All Things Angioedema, Dr. Thomas Buttgereit speaks with Dr. Isabelle Boccon-Gibod from the French ACARE center in Grenoble about the new European expert consensus on applying a treat-to-target (T2T) approach in hereditary angioedema (HAE). The discussion explores how goal-oriented care can improve consistency and patient outcomes in daily clinical practice. They discuss:🔹 What does a treat-to-target approach mean in HAE management? 🔹 How does T2T differ from traditional guideline-based treatment? 🔹 What are the short-term and long-term goals in HAE care? 🔹 Why are patient-reported outcome measures (PROMs) so important? 🔹 What challenges exist when implementing T2T in clinical practice? 🔹 How could this consensus influence future guidelines and research? Dr. Boccon-Gibod explains how structured monitoring, shared decision-making, and clearly defined treatment goals can help move HAE care closer to the ultimate aim of “normalization of life.” The episode highlights the importance of individualized care and practical strategies for improving disease control and quality of life. Key Learnings from the Episode:Treat-to-target introduces a structured, goal-oriented approach to HAE care. The approach combines short-term symptom control with long-term quality-of-life goals. Normalization of life is the ultimate treatment target in HAE. Patient-reported outcome measures are central to monitoring disease control. The AECT is an important tool for assessing HAE control in practice. Shared decision-making plays a key role in treatment planning. Clinical practice and access to therapies still vary across countries. Structured follow-up can improve consistency of care. T2T may influence future HAE guidelines and clinical research. The approach aims to improve long-term outcomes for patients with HAE. Chapters:00:00 Introduction to Angioedema and the Podcast01:04 Understanding the Treat-to-Target Approach02:15 The Role of Patient-Reported Outcome Measures10:19 Challenges in Implementing the T2T Approach12:16 Impact of Consensus on Future Research and GuidelinesDo you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form ATA: https://forms.office.com/e/ZWxx3D4Cmr
NOW PLAYING
Treat-to-Target in Hereditary Angioedema
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m